Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: Implications for treatment

Clinical Therapeutics

Volumn 33, Issue 5, 2011, Pages 528-576

  Neumiller, Joshua J ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Alogliptin; DPP 4 inhibitors; Exenatide; GLP 1 receptor agonists; Incretin therapies; Liraglutide; Saxagliptin; Sitagliptin; Type 2 diabetes; Vildagliptin

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; ATORVASTATIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ETHINYLESTRADIOL; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GRISEOFULVIN; INCRETIN; KETOCONAZOLE; LEVONORGESTREL; LIRAGLUTIDE; LISINOPRIL; METFORMIN; MEVINOLIN; PARACETAMOL; PIOGLITAZONE; RIFAMPICIN; ROSIGLITAZONE; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN; TASPOGLUTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; WARFARIN;

ACUTE PANCREATITIS; AREA UNDER THE CURVE; CLINICAL PHARMACOLOGY; DIABETIC DIET; DIARRHEA; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRY SKIN; EVENING DOSAGE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PRURITUS; INSULIN RELEASE; INSULIN TREATMENT; KIDNEY FAILURE; KINESIOTHERAPY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SKIN PRURITUS; SPLENOMEGALY; STOMACH EMPTYING; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

DIABETES MELLITUS, TYPE 2; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS;

EID: 79958743689     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.04.024     Document Type: Review

References (167)

1. Theodorakis M.J., Carlson O., Michopoulos S., et al. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 2006, 290:E550-E559.
2. Nauck M.A., Homberger E., Siegel E.G., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986, 63:492-498.
3. Boyle P.J., Shah S.D., Cryer P.E. Insulin, glucagon, and catecholamines in prevention of hypoglycemia during fasting. Am J Physiol 1989, 256(5 Pt 1):E651-E661.
4. Nauck M.A., Heimesaat M.M., Behle K., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002, 87:1239-1246.
5. Nauck M.A., Niedereichholz U., Ettler R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997, 273(5 Pt 1):E981-E988.
6. Naslund E., Gutniak M., Skogar S., et al. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998, 68:525-530.
7. Turton M.D., O'Shea D., Gunn I., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
8. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
9. Williams D.L. Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 2009, 150:2997-3001.
10. Ehses J.A., Casilla V.R., Doty T., et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003, 144:4433-4445.
11. Farilla L., Bulotta A., Hirshberg B., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144:5149-5158.
12. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
13. Kjems L.L., Holst J.J., Volund A., Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
14. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
15. Deacon C.F., Nauck M.A., Meier J., et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, 85:3575-3581.
16. Vilsboll T., Agerso H., Krarup T., Holst J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003, 88:220-224.
17. Meier J.J., Nauck M.A., Kranz D., et al. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004, 53:654-662.
18. Elahi D., McAloon-Dyke M., Fukagawa N.K., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 1994, 51:63-74.
19. Nauck M.A., Heimesaat M.M., Orskov C., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993, 91:301-307.
20. Nauck M.A., Kleine N., Orskov C., et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
21. Rachman J., Barrow B.A., Levy J.C., Turner R.C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997, 40:205-211.
22. Simonsen L., Holst J.J., Deacon C.F. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 2006, 49:706-712.
23. Byetta (exenatide) [prescribing information] 2009, Amylin Pharmaceuticals, Inc, San Diego, Calif.
24. Kothare P.A., Linnebjerg H., Skrivanek Z., et al. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther 2007, 45:114-120.
25. Soon D., Kothare P.A., Linnebjerg H., et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol 2006, 46:1179-1187.
26. Kothare P.A., Soon D.K., Linnebjerg H., et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol 2005, 45:1032-1037.
27. Blase E., Taylor K., Gao H.Y., et al. Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. J Clin Pharmacol 2005, 45:570-577.
28. Jacobsen V, Hindsberger C, Robson R, Zdravkovic M. Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment. Presented at: 43rd Annual Meeting of the European Association for the Study of Diabetes; September 17-21, 2007; Amsterdam, Netherlands.
29. Flint A., Kapitza C., Hindsberger C., Zdravkovic M. The once-daily human GLP-1 analogue liraglutide improves both absolute and baseline postprandial glucose levels. Diabetologia 2008, 51:S354.
30. Malm-Erjefält M., Ekblom M., Brøndsted L., et al. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Diabetes 2008, 57(Suppl 1):A130. Abstract.
31. Kapitza C., Flint A., Hindsberger C., Zdravkovic M. The effect of the once-daily human GLP-1 analogue liraglutide on the pharmacokinetics of paracetamol. Diabetes 2008, 57(Suppl 1):A593. Abstract.
32. Jacobsen LV, Brøndsted L, Vouis J, Zdravkovic M. A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug. Presented at: 68th Annual Scientific Sessions of the American Diabetes Association (ADA); June 6-10, 2008; San Francisco, Calif.
33. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005, 78:675-688.
34. Bergman A.J., Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006, 28:55-72.
35. Januvia (sitagliptin) [package insert] 2007, Merck & Co, Inc, Whitehouse Station, NJ.
36. Migoya E.M., Stevens C.H., Bergman A.J., et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009, 16:e165-e170.
37. Bergman A.J., Cote J., Maes A., et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 2009, 49:483-488.
38. Mistry G.C., Bergman A.J., Luo W.L., et al. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects. J Clin Pharmacol 2007, 47:159-164.
39. Mistry G.C., Bergman A.J., Zheng W., et al. Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. Br J Clin Pharmacol 2008, 66:36-42.
40. Wright D.H., Herman G.A., Maes A., Liu Q., et al. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 2009, 49:1157-1167.
41. Onglyza (saxagliptin) [package insert] 2009, Bristol-Myers Squibb Co, Princeton, NJ.
42. Galvus (vildagliptin) [summary of products characteristics] 2007, Novartis Europharm Ltd, West Sussex, UK.
43. He H., Tran P., Yin H., et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 2009, 37:536-544.
44. Ayalasomayajula S.P., Dole K., He Y.L., et al. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007, 23:2913-2920.
45. He Y.L., Ligueros-Saylan M., Sunkara G., et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008, 48:85-95.
46. He Y.L., Sabo R., Picard F., et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009, 25:1265-1272.
47. Serra D., He Y.L., Bullock J., et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. Int J Clin Pharmacol Ther 2008, 46:349-364.
48. Brown N.J., Byiers S., Carr D., Maldonado M., Warner B.A. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009, 54:516-523.
49. Covington P., Christopher R., Davenport M., et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther 2008, 30:499-512.
50. Christopher R., Covington P., Davenport M., et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther 2008, 30:513-527.
51. Karim A., Fleck P., Hetman L., et al. Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment. Diabetes 2008, 57(Suppl 1):A160. Abstract.
52. Covington P, Christopher R, Davenport M, et al. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects. Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-26, 2007; Chicago, Ill.
53. Eng J., Kleinman W.A., Singh L., et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
54. Amylin and Lilly announce FDA approval of Byetta (exenatide) injection [news release] PR Newswire, Accessed October 14, 2009. http://www2.prnewswire.com/cgi-bin/stories.pl?ACCT=104%26STORY=/www/story/04-29-2005/0003494121%26EDATE=
55. Goke R., Fehmann H.C., Linn T., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268:19650-19655.
56. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53:2181-2189.
57. Perry T., Greig N.H. The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol Sci 2003, 24:377-383.
58. Kolterman O.G., Kim D.D., Shen L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
59. Linnebjerg H., Kothare P.A., Park S., et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007, 64:317-327.
60. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
61. Kim D., MacConell L., Zhuang D., et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007, 30:1487-1493.
62. Iwamoto K., Nasu R., Yamamura A., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J 2009, 56:951-962.
63. FDA requests more data for once-weekly exenatide Medscape Medical News, Accessed May 18, 2011. http://www.medscape.com/viewarticle/731618.
64. Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
65. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43:1664-1669.
66. Bjornsdottir I., Olsen A., Larsen U., et al. Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Diabetologia 2008, 51(Suppl 1):S356.
67. Steensgaard D.B., Thomsen J.K., Olsen H.B., Knudsen L.B. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes 2008, 57(Suppl 1):A164. Abstract.
68. Agerso H., Jensen L.B., Elbrond B., et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202.
69. Deacon C.F., Pridal L., Klarskov L., et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996, 271(3 Pt 1):E458-E464.
70. Flint A, Nazzal K, Jagielski P, et al. Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide. Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-26, 2007; Chicago, Ill.
71. Victoza (liraglutide) [package insert] 2009, Novo Nordisk A/S, Bagsværd, Denmark.
72. Victoza US (liraglutide) [prescribing information] 2010, Novo Nordisk Inc, Princeton, NJ.
73. Victoza (liraglutide) [prescribing information] 2010, Novo Nordisk A/S, Bagsvaerd, Denmark.
74. Novo Nordisk's Victoza (liraglutide) receives marketing authorisation in Europe (3 July 2009) Novo Nordisk, Accessed March 25, 2010. http://www.novonordisk.com/press/sea/sea.asp?sNewsTypeGUID=%26lMonth=%26lYear=%26sLanguageCode=%26sSearchText=%26sShowNewsItemGUID=fef45783-0017-45f7-8185-ad751bad7019%26sShowLanguageCode=en-GB.
75. Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe [news release] Novo Nordisk A/S, Accessed March, 25, 2010. http://press.novonordisk-us.com/index.php?s=43%26item=17.
76. Novo Nordisk's Victoza Receives FDA Approval for Adults With Type 2 Diabetes (25 Jan 2010) Novo Nordisk, Accessed March 25, 2010. http://press.novonordisk-us.com/index.php?s=43%26item=233.
77. Nauck M., Ratner R., Kapitza C., et al. Treatment with the human once-weekly GLP-1 analogue taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled with metformin alone: a double-blind placebo-controlled study. Diabetes Care 2009, 32:1237-1243.
78. Kapitza C., Klein O., Obach R., et al. Long acting human GLP-1 analogue R1583: safety, pharmacokinetic and pharmacodynamic properties after a single administration in subjects with type 2 diabetes. Diabetes 2008, 57:506-P.
79. Roche moves investigational diabetes drug, Taspoglutide, into Phase III clinical trials Hoffmann-La Roche Ltd, Accessed October 14, 2009. http://www.roche.com/med-cor-2008-06-10.
80. Bush M.A., Matthews J.E., De Boever E.H., et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009, 11:498-505.
81. Matthews J.E., Stewart M.W., De Boever E.H., et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 93:4810-4817.
82. Stewart M.W., Matthews J., De Boever E.H., et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. Diabetes 2008, 57(Suppl 1):A154.
83. GSK initiates phase III programme for novel type 2 diabetes medication, Syncria (albiglutide) GlaxoSmithKline, Accessed March 25 2010. http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10025.htm.
84. Thornberry N.A., Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 2009, 23:479-486.
85. Chemical structures Accessed August 5, 2010. http://wikimediafoundation.org/wiki/Home.
86. Lankas G.R., Leiting B., Roy R.S., et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54:2988-2994.
87. Herman G.A., Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612-4619.
88. Bergman A.J., Cote J., Yi B., et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007, 30:1862-1864.
89. Herman G, Bergman A, Wagner JA. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug- drug interactions (DDI). Presented at: 42nd Annual Meeting of the European Association for the Study of Diabetes; September 14- 17, 2006; Copenhagen, Denmark.
90. Augeri D.J., Robl J.A., Betebenner D.A., et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:5025-5037.
91. Wang A., Dorso C., Kopcho L.M., et al. Implications of the prolonged dissociation rate of saxagliptin, a highly potent and selective DPP4 inhibitor, on plasma DPP measurements. Diabetes 2008, 57(Suppl 1):A576-A577. Abstract.
92. Boulton DW, Geraldes M. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily oral doses of saxagliptin for 2 weeks in type 2 diabetic and healthy subjects. Presented at: 67th Annual Scientific Sessions of the American Diabetes Association; June 22-26, 2007; Chicago, Ill.
93. Patel C., Castaneda L., Frevert U., et al. Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects. Diabetes 2008, 57(Suppl 1):A160. Abstract.
94. Patel CG, Li L, Komoroski B, Boulton D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and glyburide in healthy subjects. Presented at: 2007 Annual Meeting of the American College of Clinical Pharmacy; October 14-17, 2007; Denver, Colo. Abstract 212.
95. Patel C, Li L, Komoroski B, Boulton D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and metformin in healthy subjects. Presented at: 2007 Annual Meeting of the American College of Clinical Pharmacy; October 14-17, 2007; Denver, Colo. Abstract 213.
96. Patel C, Li L, Komoroski B, Boulton D. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and pioglitazone in healthy subjects. Presented at: 2007 Annual Meeting of the American College of Clinical Pharmacy; October 14-17, 2007; Denver, Colo. Abstract 226.
97. Villhauer E.B., Brinkman J.A., Naderi G.B., et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003, 46:2774-2789.
98. Brandt I., Joossens J., Chen X., et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol 2005, 70:134-143.
99. He Y.L., Serra D., Wang Y., et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007, 46:577-588.
100. He Y.L., Sadler B.M., Sabo R., et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007, 46:787-802.
101. He Y.L., Sabo R., Campestrini J., et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007, 63:677-686.
102. Pharmiweb Galvus, a new oral treatment for type 2 diabetes, receives positive opinion following changes to European prescribing information [news release] Accessed May 19, 2011. http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=2973.
103. Lavelle E. Novartis says FDA wants new Galvus study; shares drop (update9) 2007, Bloomberg News, Accessed March 25, 2010. http://www.bloomberg.com/apps/news?pid=20601085%26sid=aiy45mXjCb1w%26refer=europe.
104. Lee B., Shi L., Kassel D.B., Asakawa T., et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol 2008, 589:306-314.
105. Karim A., Laurent A., Munsaka M., et al. Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. J Clin Pharmacol 2009, 49:1210-1219.
106. Karim A., Fleck P., Harris S., et al. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects. Clin Pharmacol Ther 2008, 83(Suppl 1). abstract PI-13, Accessed March 25, 2010. http://www.nature.com/clpt/journal/v83/n1s/pdf/clpt200838a.pdf.
107. Karim A., Chiselko P., Fleck P., et al. Lack of effect of cyclosporine on the single dose pharmacokinetics of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in health male subjects. Clin Pharmacol Ther 2008, 83(Suppl 1). abstract PI-15.
108. Takeda provides update on the investigational fixed-dose combination of alogliptin and Actos (pioglitazone HCl) [news release] Takeda Pharmaceutical Co Ltd, Accessed March 25, 2010. http://www.takeda.com/press/article_34936.html.
109. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
110. Moretto T.J., Milton D.R., Ridge T.D., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460.
111. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
112. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
113. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083-1091.
114. Zinman B., Hoogwerf B.J., Duran G.S., et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007, 146:477-485.
115. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
116. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
117. Marre M., Shaw J., Brandle M., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
118. Nauck M., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
119. Russell-Jones D., Vaag A., Schmitz O., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
120. Zinman B., Gerich J., Buse J.B., et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
121. Rosenstock J., Gumprecht J., Szyprowska E., et al. Pharmacokinetics of liraglutide vs exenatide in type 2 diabetes: sustained vs fluctuating concentrations over 24 hours. Diabetes 2009, 58(Suppl 1):A150. Abstract.
122. Edwards C.M., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001, 281:E155-E161.
123. Juhl C.B., Hollingdal M., Sturis J., et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002, 51:424-429.
124. Raun K., von V.P., Gotfredsen C.F., et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8-15.
125. Raun K., von V.P., Knudsen L.B. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity (Silver Spring) 2007, 15:1710-1716.
126. Zhao T., Parikh P., Bhashyam S., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-1113.
127. Noyan-Ashraf M.H., Momen M.A., Ban K., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
128. Nystrom T., Gutniak M.K., Zhang Q., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215.
129. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
130. Ban K., Noyan-Ashraf M.H., Hoefer J., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
131. Plutzky J, Garber AJ, Falahati A, et al. The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials. Presented at: European Society of Cardiology Congress 2009; August 29-September 2, 2009; Barcelona, Spain.
132. Ghofaili K.A., Fung M., Ao Z., et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007, 83:24-28.
133. Vilsboll T., Brock B., Perrild H., et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008, 25:152-156.
134. Chen J., Couto F.M., Minn A.H., Shalev A. Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 2006, 346:1067-1074.
135. Bregenholt S., Moldrup A., Blume N., et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005, 330:577-584.
136. New drug application for exenatide once weekly accepted for review by FDA [news release] Eli Lilly and Company, Accessed September 14, 2009. http://newsroom.lilly.com/releasedetail.cfm?releaseid=394708.
137. Bain S.C., Stephens J.W. Exenatide and pancreatitis: an update. Expert Opin Drug Saf 2008, 7:643-644.
138. Noel R.A., Braun D.K., Patterson R.E., Bloomgren G.L. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009, 32:834-838.
139. Dore D.D., Seeger J.D., Arnold C.K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009, 25:1019-1027.
140. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
141. Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
142. Hanefeld M., Herman G.A., Wu M., et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin 2007, 23:1329-1339.
143. Hermansen K., Kipnes M., Luo E., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:733-745.
144. Nauck M.A., Meininger G., Sheng D., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205.
145. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49:2564-2571.
146. Raz I., Chen Y., Wu M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24:537-550.
147. Rosenstock J., Brazg R., Andryuk P.J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28:1556-1568.
148. Scott R., Loeys T., Davies M.J., Engel S.S. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10:959-969.
149. Hollander P., Li J., Allen E., Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009, 94:4810-4819. CV181-013 Investigators.
150. Chacra A.R., Tan G.H., Apanovitch A., et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009, 63:1395-1406.
151. DeFronzo R.A., Hissa M.N., Garber A.J., et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32:1649-1655.
152. Bosi E., Camisasca R.P., Collober C., et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, 30:890-895.
153. Ferrannini E., Fonseca V., Zinman B., et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11:157-166.
154. Garber A.J., Schweizer A., Baron M.A., et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007, 9:166-174.
155. Garber A.J., Foley J.E., Banerji M.A., et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008, 10:1047-1056.
156. Pi-Sunyer F.X., Schweizer A., Mills D., Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007, 76:132-138.
157. Schweizer A., Couturier A., Foley J.E., Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 2007, 24:955-961.
158. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008, 31:2315-2317.
159. Nauck M.A., Ellis G.C., Fleck P.R., et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009, 63:46-55.
160. Pratley R.E., Kipnes M.S., Fleck P.R., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab 2009, 11:167-176.
161. Pratley R.E., Reusch J.E., Fleck P.R., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2009, 25:2361-2371. for the Alogliptin Study 009 Group.
162. Riche D.M., East H.E., Riche K.D. Impact of sitagliptin on markers of beta-cell function: a meta-analysis. Am J Med Sci 2009, 337:321-328.
163. Mu J., Woods J., Zhou Y.P., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55:1695-1704.
164. El-Ouaghlidi A., Rehring E., Holst J.J., et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007, 92:4165-4171.
165. Vella A., Bock G., Giesler P.D., et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007, 56:1475-1480.
166. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
167. Richter B., Bandeira-Echtler E., Bergerhoff K., Lerch C.L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008, (2). CD006739.